| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Clinical Neurosciences, Guy’s, King’s and St. Thomas’ School of Medicine, Guy’s Hospital, London, UK.
Address correspondence and reprint requests to Dr. R.D.M. Hadden, Department of Clinical Neurosciences, Hodgkin Building, Guy’s, King’s and St. Thomas’ School of Medicine, Guy’s Hospital, London SE1 9RT, UK.
OBJECTIVE: To test the safety and efficacy of interferon ß-1a (IFN-ß) in treatment-resistant chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
BACKGROUND: Current treatment regimens leave 4% to 30% of patients with CIDP with moderate or severe disability. IFN-ß has been reported as beneficial in one treatment-resistant patient.
METHODS: Ten consecutive treatment-resistant patients were randomized in a double-blind, crossover design to receive placebo or IFN-ß (3 MIU for 2 weeks and then 6 MIU for 10 weeks) subcutaneously three times weekly, followed by 4 weeks without treatment, and then the opposite treatment for 12 weeks. The primary outcome measure was "clinically important" improvement by specified amounts in any three of eight clinical measures: timed 10-m walk, Ambulation Index, expanded Medical Research Council sum score, nine-hole peg test time, Functional Independence Measure, Hammersmith Motor Ability, a new Guy’s Neurological Disability Scale, and the EuroQoL quality-of-life scale. These and motor median nerve conduction studies were measured before and after 12 weeks of each treatment.
RESULTS: Clinically important improvement was observed in one patient while taking IFN-ß and two patients while taking placebo. There was no significant difference between IFN-ß and placebo in the change in any of the individual clinical or neurophysiological measures between the beginning and end of treatment. There were no serious adverse events.
CONCLUSION: This trial shows that IFN-ß is safe but not efficacious in treatment-resistant CIDP.
This article has been cited by other articles:
|
|
 |
|
  H. C. Lehmann, G. Meyer zu Horste, B. C. Kieseier, and H.-P. Hartung Review: Pathogenesis and treatment of immune-mediated neuropathies Therapeutic Advances in Neurological Disorders, July 1, 2009; 2(4): 261 - 281. [Abstract] [PDF]
|
|
|
|
 |
|
 D Fialho, Y-C Chan, D C Allen, M M Reilly, and R A C Hughes Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate J. Neurol. Neurosurg. Psychiatry, April 1, 2006; 77(4): 544 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R Overell and H. J Willison Chronic inflammatory demyelinating polyradiculoneuropathy: classification and treatment options Practical Neurology, April 1, 2006; 6(2): 102 - 110. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ekstein, E. Linetsky, O. Abramsky, and D. Karussis Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis Neurology, August 9, 2005; 65(3): 456 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Odaka, M Tatsumoto, K Susuki, K Hirata, and N Yuki Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin J. Neurol. Neurosurg. Psychiatry, August 1, 2005; 76(8): 1115 - 1120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. H. Van Asseldonk, L. H. Van den Berg, S. Kalmijn, J. H. J. Wokke, and H. Franssen Criteria for demyelination based on the maximum slowing due to axonal degeneration, determined after warming in water at 37{degrees}C: diagnostic yield in chronic inflammatory demyelinating polyneuropathy Brain, April 1, 2005; 128(4): 880 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Koller, B. C. Kieseier, S. Jander, and H.-P. Hartung Chronic Inflammatory Demyelinating Polyneuropathy N. Engl. J. Med., March 31, 2005; 352(13): 1343 - 1356. [Full Text] [PDF]
|
|
|
|
|
|
J. Pritchard, I. A. Gray, Z. R. Idrissova, B. R.F. Lecky, I. J. Sutton, A. V. Swan, H. J. Willison, J. B. Winer, and R. A.C. Hughes A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barre syndrome Neurology, November 11, 2003; 61(9): 1282 - 1284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. V. Toyka and R. Gold The pathogenesis of CIDP: Rationale for treatment with immunomodulatory agents Neurology, April 22, 2003; 60(90083): S2 - 7. [Abstract] [Full Text]
|
|
|
|
|
|
J.-M. Vallat, A.F. Hahn, J.-M. Leger, D.P. Cros, L. Magy, F. Tabaraud, P. Bouche, and P.-M. Preux Interferon beta-1a as an investigational treatment for CIDP Neurology, April 22, 2003; 60(90083): S23 - 28. [Abstract] [Full Text]
|
|
|
|
|
|
C. L. Koski Therapy of CIDP and related immune-mediated neuropathies Neurology, December 24, 2002; 59(90126): S22 - 27. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. J. Pittock, D. Meldrum, and O. Hardiman The "Spray Can" Sign: Validation of a Clinical Observation in Chronic Inflammatory Demyelinating Polyneuropathy Arch Neurol, October 1, 2002; 59(10): 1637 - 1640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. S.J. Merkies, P. I.M. Schmitz, F. G.A. van der Meche, J. P.A. Samijn, and P. A. van Doorn Quality of life complements traditional outcome measures in immune-mediated polyneuropathies Neurology, July 9, 2002; 59(1): 84 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.R. Mendell, R.J. Barohn, M.L. Freimer, J.T. Kissel, W. King, H.N. Nagaraja, R. Rice, W.W. Campbell, P.D. Donofrio, C.E. Jackson, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy Neurology, February 27, 2001; 56(4): 445 - 449. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
